News

George Martin, MD, reveals cutting-edge treatments for vitiligo, psoriasis, and psoriatic arthritis at Maui Derm NP+PA Fall 2025, enhancing patient care strategies.

Matthew Bruno, PA-C, explores the transformative impact of AI at Maui Derm NP+PA Fall, emphasizing its benefits, ethical concerns, and the need for clinician engagement.

Discover expert insights on treating uncommon conditions like lichen planus, CSU, and polymorphous light eruption from Maui Derm NP+PA Fall 2025.

Explore common dermatological nail disorders and innovative surgical techniques presented by Phoebe Rich, MD, at Maui Derm NP+PA Fall 2025.

At Maui Derm NP+PA Fall 2025, Ted Rosen, MD, and Vikash Oza, MD, discuss emerging infectious diseases in dermatology, highlighting new treatments and diagnostic challenges for clinicians.

Catch up on coverage from the second day of the Maui Derm NP+PA Fall 2025 conference held in Nashville, Tennessee.

Discover expert insights on cutaneous oncology from George Martin, MD, focusing on innovative treatments for skin cancers at Maui Derm NP+PA Fall.

Discover key insights from the Maui Derm NP+PA Fall 2025 Conference on advances in dermatology, including new treatments and research findings.

Discover groundbreaking dermatologic therapies and new drug approvals presented at Maui Derm NP+PA Fall, featuring insights from experts George Martin, MD, and Ted Rosen, MD.

Berdazimer shows promise for treating MC in pediatric patients, even in those with a history of atopic dermatitis, according to a poster at Maui Derm NP+PA Fall.

Catch up on coverage from the first day of the Maui Derm NP+PA Fall 2025 conference held in Nashville, Tennessee.

Elena Hawryluk, MD, PhD, highlights innovative pediatric dermatology at Maui Derm NP+PA Fall, emphasizing education and advancements in tumor genetics.

Preview the Maui Derm NP+PA Fall 2025 Conference with program director George Martin, MD, featuring cutting-edge education and expert insights in Nashville.

Preview Maui Derm NP+PA Fall 2025 Conference's 4 days of cutting-edge dermatology insights, networking, and expert-led sessions in Nashville.

Phase 1a results showing STAR-0310’s half-life of up to 68 days, durable cytokine inhibition, and a favorable safety profile will be presented in full at EADV 2025.

Evidence presented at EADV supports upadacitinib’s long-term use in atopic dermatitis and other inflammatory conditions.

Patients switched from placebo to remibrutinib at week 24 showed similar reductions in autoantibodies by week 52.

At week 16, up to 61% mean EASI reduction was observed in high-dose patients versus 31% in placebo.

Catch up on coverage from the third day of the European Academy of Dermatology and Venereology Congress 2025 held in Paris, France.

Treatment with APG777 led to a significant 71.0% reduction in EASI scores from baseline to week 16, compared to a 33.8% reduction with placebo, according to data presented at EADV 2025.

Galvokamig, a biologic targeting IL-13 and IL-17A/F, demonstrated significant benefits in moderate to severe atopic dermatitis.

Late-breaking EADV 2025 presentations highlighted positive efficacy outcomes in the adolescent population and pooled safety data across 5 phase 2b and phase 3 trials of delgocitinib cream.

Tiffany Mayo, MD, recently moderated a Dermatology Times Case-Based Roundtable event to discuss topical innovation, systemic options, and patient-centered factors when treating atopic dermatitis.

Together with earlier trials presented at EADV, these findings support OX40 receptor inhibition as a promising therapeutic approach for AD.

The oral degrader produced biomarker reductions consistent with or superior to dupilumab, according to data presented at EADV 2025.

At EADV 2025, she showcased how OX40 and JAK inhibition offer complementary approaches to long-term disease control.

Catch up on coverage from the second day of the European Academy of Dermatology and Venereology Congress 2025 held in Paris, France.

Nicole Harter, MD, explores ruxolitinib 1.5% cream for pediatric atopic dermatitis, offering a novel, effective treatment option for children aged 2 to 11.

Denifanstat shows promising results in treating moderate to severe acne vulgaris, achieving significant efficacy and safety at the EADV Congress 2025.

Ruxolitinib cream has become the first topical JAK inhibitor available for pediatric atopic dermatitis (AD) in the US.